Research Progress of Granulocytic Myeloid-derived Suppressor Cells
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2023.106.28
- Author:
Chaodan YANG
1
;
Rui ZHU
2
;
Yuting ZHANG
3
;
Lisha YING
2
;
Jiamin WANG
1
;
Pan LIU
2
;
Dan SU
1
Author Information
1. School of Molecular Medicine, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
2. Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute
of Medicine, Chinese Academy of Sciences, Hangzhou 310022, China.
3. Postgraduate Training Base Alliance of Wenzhou Medical
University, Zhejiang Cancer Hospital, Hangzhou 310022, China.
- Publication Type:Journal Article
- Keywords:
Granulocytic myeloid-derived suppressor cells;
Immune microenvironment;
Immunotherapy;
Lung neoplasms;
Targeted therapy
- MeSH:
Humans;
Myeloid-Derived Suppressor Cells;
Carcinoma, Non-Small-Cell Lung;
Lung Neoplasms/drug therapy*;
T-Lymphocytes;
Immunotherapy;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2024;27(1):65-72
- CountryChina
- Language:Chinese
-
Abstract:
Granulocytic myeloid-derived suppressor cells (G-MDSCs) are one of the main subgroups of MDSCs, which are widely enriched in most cancers. It can inhibit the killing function of T-lymphocyte through the expression of arginase-1 (Arg-1) and reactive oxygen species (ROS), reshape the tumor immune microenvironment, and promote the occurrence and development of tumors. In recent years, more and more studies have found that G-MDSCs are significantly correlated with the prognosis and immunotherapy efficacy of patients with non-small cell lung cancer, and the use of drugs specifically targeting the recruitment, differentiation and function of G-MDSCs can effectively inhibit tumor progression. This article reviews the immunosuppressive effect of G-MDSCs in non-small cell lung cancer and the progress of related pathway targeting drugs.
.
